摘要
我们于1986年曾经报道扶绥县肝癌高发区高危险人群口服左旋咪唑预防肝癌的第2次实验研究结果.本文报道对该地区原观察人群停服药3年后的随访结果.实验组4570人(年),发生肝癌7例,发生率为153.2/10万;对照组3304人(年),肝癌20例,发生率为605.3/10万,为实验组的3.95倍.表明左旋咪唑预防肝癌的效果仍存在.但已明显下降.
A 3 years survey, after completing a field experiment of oral administrating levamisole to prevent PHC, was performed in a PHC high risk population in Fu-Sui countxy, Guangxi.Since 1986, when we published the result of our second field experiment about PHC prevention by oral administ-ration of levamisole, there were only 7 PHC deaths found in the members of prior experiment group (4 570 person-years observed) ,while 20 of the control subjects who had been given placebo in the prior field trial died of the same cause (total observed person-year was 3 304).From this result, it was obvious that the risk of developing PHC among those who had been administ-rated levamisole in our second field experiment was still much lower than that of the prior control adults.(the incidence rates were 153.2/10~5VS 605.3/10~5, the ratio of the risks was 1∶3.95).It was shown in this survey that the effect of preventing PHC still existed even after stopping the administration of levamisole, although it had already weakened.
关键词
左旋咪唑
预防
肝癌
Levamisole
Prevention
Liver Cancer
